Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Aurinia Pharmaceuticals Inc (NASDAQ : AUPH ) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Quote
| Last: | $15.93 |
|---|---|
| Change Percent: | -2.98% |
| Open: | $16.09 |
| Close: | $16.42 |
| High: | $16.12 |
| Low: | $15.77 |
| Volume: | 275,966 |
| Last Trade Date Time: | 04/15/2026 11:34:57 am |
Stock Data
| Market Cap: | $1,932,123,392 |
|---|---|
| Float: | 126,527,384 |
| Insiders Ownership: | 2.24% |
| Institutions: | 102 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.auriniapharma.com |
| Country: | CA |
| City: | Edmonton |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about Aurinia Pharmaceuticals Inc (NASDAQ: AUPH).
